Vitality Biopharma Inc(OTCMKTS:VBIO) has seen a drop over the past few weeks since topping $2.50 a share earlier this year. The stock does have runner in its blood skyrocketing last november from well under $1 a share to highs over $4.
VBIO operates in the red hot Marijuana industry that has quickly turned into a multi-billion dollar massive growth market that is sweeping across the Country with many new states legalizing the drug including California, Nevada, Maine, and Massachusetts on November 8.
Vitality Biopharma Inc(OTCMKTS:VBIO) says it is dedicated to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders. VBIO product pipeline includes Cannabosides – VITA-100 for gastrointestinal disorders, including inflammatory bowel disease and irritable bowel syndrome; Cannabosides – VITA-210 for muscle spasticity in multiple sclerosis and rare white matter disorders; and Cannabosides for epilepsy, schizophrenia, substance abuse, and Huntington’s disease.
Vitality Biopharma has developed a new class of cannabinoid prodrug, known as cannabosides, which upon ingestion can enable the selective delivery of THC and cannabidiol (CBD) to the gastrointestinal tract. Site-specific delivery could enable oral drug formulations of cannabinoids to provide therapeutic benefits while reducing or avoiding the systemic delivery of THC into the bloodstream. Currently, high concentrations of psychoactive THC in the brain limit the dose of cannabinoids that can be used elsewhere in the body for treatment of pain and inflammation.
Independent clinical trial results suggest that cannabinoids will help induce remission in Crohn’s disease patients, and that the vast majority of inflammatory bowel disease patients experience symptomatic relief, including more than 75% of patients who report improvement in visceral pain and abdominal cramping. Approximately 1.4 million Americans are affected by inflammatory bowel diseases, including Crohn’s disease and ulcerative colitis. Most patients are diagnosed before age 30 and require life-long treatment.
In addition to providing targeted delivery, cannabosides could enable a better tasting formulation for improved patient compliance, better oral bioavailability that provides safer and more reliable dosing, and a delayed release mechanism that enables patients using these medications to have long-lasting, overnight relief.
To Find out the inside Scoop on VBIO Subscribe to Microcapdaily.com Right Now by entering your Email in the box below
A prodrug is a medication or compound that, after administration, is metabolized (i.e., converted within the body) into a pharmacologically active drug. Prodrugs are often designed to improve bioavailability when a drug itself is poorly absorbed from the gastrointestinal tract, or to overcome other issues that make molecules unappealing candidates for future development efforts. A prodrug may for instance be used to selectively target a specific tissue or organ, such as the brain or gut, which enables the drug to have a more targeted effect. Prodrugs have been around for a while, with Aspirin, acetylsalicylic acid, first made by Felix Hoffmann at Bayer in 1897, a classic example of a synthetic prodrug of salicylic acid. As of 2015, there were approximately 15 prodrugs that had been classified as blockbusters, defined as having annual sales in excess of $1 billion.
On July 19 VBIO announced positive preclinical efficacy results for its gut-targeted cannabosides in the treatment of colitis. Vitality Biopharma has developed a new class of cannabinoid prodrugs, known as cannabosides, which upon ingestion can be targeted and limited to the gastrointestinal tract, thereby avoiding drug psychoactivity and unforeseen side effects. In a preclinical model of inflammatory bowel disease (IBD), cannabosides were able to reduce weight loss, decrease damage to the colon, and markedly improve gastrointestinal health compared to the placebo controls.
Vitality’s cannabosides were successful in treatment of an acute model of colitis (DSS), which is traditionally viewed as very challenging, given that certain FDA-approved therapies including corticosteroids and TNF-alpha inhibitors have been shown to be ineffective for treating this model. The positive preclinical efficacy results with cannabosides are required in order for the Company to progress into first-in-man clinical trials.
We have a Monster Pick Coming. Subscribe Right Now!
Currently trading at a $38 million market valuation VBIO has minimal cash or revenues; VBIO is Stevia First Corp. STEV reincarnated. The stock has clearly caught the eye of investors with their new class of cannabinoid products, known as cannabosides. The Company has been making headway in the booming pot sector as they develop cannabinoid prodrug pharmaceuticals, as well as unlock the power of cannabinoids for the treatment of serious neurological and inflammatory disorders. We will be updating on VBIO when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with VBIO.
Sign Up now for our 100% FREE Penny Stock Newsletter
Disclosure: we hold no position in VBIO either long or short and we have not been compensated for this article.